Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Operating Leases (2019 - 2025)

Cardiff Oncology's Operating Leases history spans 7 years, with the latest figure at $284000.0 for Q3 2025.

  • For Q3 2025, Operating Leases fell 70.99% year-over-year to $284000.0; the TTM value through Sep 2025 reached $284000.0, down 70.99%, while the annual FY2024 figure was $813000.0, 44.24% down from the prior year.
  • Operating Leases for Q3 2025 was $284000.0 at Cardiff Oncology, down from $464000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $3.0 million in Q2 2022 and bottomed at $8000.0 in Q1 2021.
  • The 5-year median for Operating Leases is $1.5 million (2023), against an average of $1.5 million.
  • The largest annual shift saw Operating Leases skyrocketed 30375.0% in 2022 before it crashed 70.99% in 2025.
  • A 5-year view of Operating Leases shows it stood at $2.6 million in 2021, then decreased by 20.56% to $2.0 million in 2022, then fell by 28.53% to $1.5 million in 2023, then plummeted by 44.24% to $813000.0 in 2024, then tumbled by 65.07% to $284000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Operating Leases are $284000.0 (Q3 2025), $464000.0 (Q2 2025), and $640000.0 (Q1 2025).